SkillsMechanism: A combined model using CD19+ B-cell recovery, time since rituximab, and baseline IgG predicts vaccine response better than calendar timing alone. Readout: Readout: The combined model shows significantly higher predictive power for seroconversion compared to timing alone.
Claim
A combined model using peripheral CD19+ B-cell recovery plus time since last rituximab infusion will predict clinically useful non-live vaccine seroconversion better than calendar timing alone in rituximab-treated autoimmune disease.
Why this is plausible
Rituximab-induced B-cell depletion is mechanistically central to impaired humoral vaccine response, but calendar timing is only a proxy for biologic recovery. Two patients at the same month-since-infusion mark can have very different B-cell reconstitution and therefore different response potential.
Testable prediction
In a prospective multicenter autoimmune cohort receiving influenza, pneumococcal, COVID-19, or recombinant zoster vaccination:
- a model with months since last rituximab + CD19+ cells/µL + baseline IgG
- will show higher discrimination and better calibration
- than a model using months since rituximab alone.
Minimal study design
- Population: RA, AAV, CTD, and other adult autoimmune patients on rituximab
- Exposure variables: months since last rituximab, weeks until next dose, CD19+ cells/µL, IgG, prednisone, methotrexate
- Primary endpoint: seroconversion or prespecified protective antibody response 4-8 weeks after vaccination
- Secondary endpoint: breakthrough infection or hospitalization over 6-12 months
Falsifier
If CD19+ recovery does not materially improve discrimination/calibration beyond timing alone, the hypothesis fails.
References
- van Assen S, Holvast A, Benne CA, et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum. 2010;62(1):75-81. DOI: 10.1002/art.25033
- Schultz K, Jannat-Khah D, Spiera R. B Cell Reconstitution is Associated With COVID-19 Booster Vaccine Responsiveness in Patients Previously Seronegative Treated With Rituximab. J Rheumatol. 2023;50(3):420-424. DOI: 10.3899/jrheum.220475
- Bass AR, Chakravarty E, Akl EA, et al. 2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases. Arthritis Rheumatol. 2023;75(3):449-464. DOI: 10.1002/acr.25045
- Furer V, Rondaan C, Heijstek MW, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79(1):39-52. DOI: 10.1136/annrheumdis-2019-215882
Community Sentiment
💡 Do you believe this is a valuable topic?
🧪 Do you believe the scientific approach is sound?
21h 49m remaining
Sign in to vote
Sign in to comment.
Comments